Small Molecules Targeting Programmed Cell Death in Breast Cancer Cells

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Targeted chemotherapy offers effective cancer treatment with fewer side effects by acting on specific molecular targets in tumor cells.
• Programmed cell death pathways, including apoptosis and autophagy, are emerging as crucial therapeutic targets in cancer treatment.
• Triple-negative breast cancer (TNBC) is a heterogeneous subtype with a poor prognosis and lacks specific molecular targets, leading to significant morbidity and mortality.

Purpose of the Study:

• To review small molecules targeting autophagy and apoptosis for inducing cell death in TNBC cells.
• To highlight strategies for overcoming chemoresistance in heterogeneous breast cancer, particularly TNBC.
• To present promising preclinical data on novel therapeutic approaches for TNBC.

Main Methods:

• Literature review of preclinical studies on small molecules targeting cancer cell death pathways.
• Analysis of research identifying mechanisms of chemoresistance in TNBC.
• Focus on small molecules that modulate autophagy and apoptosis.

Main Results:

• Several small molecules demonstrate preclinical efficacy in inducing cell death in TNBC cells.
• Targeting compensatory mechanisms can alleviate drug resistance in cancer therapy.
• Small molecules modulating autophagy and apoptosis show potential for TNBC treatment.

Conclusions:

• Small molecules targeting apoptosis and autophagy pathways represent a promising strategy for TNBC treatment.
• Further research into these small molecules could lead to improved therapeutic outcomes for TNBC patients.
• Addressing chemoresistance through targeted induction of cell death is critical for improving TNBC prognosis.